Background: The need for effective, long-term treatment for recurrent or chronic, treatment-resistant depression is well established.
Methods: This naturalistic follow-up describes outpatients with nonpsychotic major depressive (n = 185) or bipolar (I or II) disorder, depressed phase (n = 20) who initially received 10 weeks of active (n = 110) or sham vagus nerve stimulation (VNS) (n = 95). The initial active group received another 9 months, while the initial sham group received 12 months of VNS. Participants received antidepressant treatments and VNS, both of which could be adjusted.
Results: The primary analysis (repeated measures linear regression) revealed a significant reduction in 24-item Hamilton Rating Scale for Depression (HRSD(24)) scores (average improvement, .45 points [SE = .05] per month (p < .001). At exit, HRSD(24) response rate was 27.2% (55/202); remission rate (HRSD(24) < or = 9) was 15.8% (32/202). Montgomery Asberg Depression Rating Scale (28.2% [57/202]) and Clinical Global Impression-Improvement (34.0% [68/200]) showed similar response rates. Voice alteration, dyspnea, and neck pain were the most frequently reported adverse events.
Conclusions: These 1-year open trial data found VNS to be well tolerated, suggesting a potential long-term, growing benefit in treatment-resistant depression, albeit in the context of changes in depression treatments. Comparative long-term data are needed to determine whether these benefits can be attributed to VNS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopsych.2005.05.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The ketamine chameleon: history, pharmacology, and the contested value of experience.
Expert Rev Clin Pharmacol
January 2025
Department of Psychiatry, McGill University, Montréal, Canada.
Introduction: Since its synthesis in 1962, ketamine has been widely used in diverse medical contexts, from anesthesia to treatment-resistant depression. However, interpretations of ketamine's subjective effects remain polarized. Biomedical frameworks typically construe the drug's experiential effects as dissociative or psychotomimetic, while psychedelic paradigms emphasize the potential therapeutic merits of these non-ordinary states.
View Article and Find Full Text PDFCortical hypometabolism as a predictor of intermittent theta burst stimulation response in treatment-resistant depression patients: An open-label study.
Indian J Psychiatry
December 2024
Department of Nuclear Medicine, AIIMS, Bilaspur, Himachal Pradesh, India.
Background: Intermittent theta burst stimulation (iTBS) is an accepted and approved brain stimulation technique to treat patients with treatment-resistant depression.
Aim: Using neuroimaging, this open-label study aimed to predict the response by observing glucose metabolism with the help of 18-FDG PET scan.
Methods: A total of 25 treatment-resistant depression patients received 15 sessions of iTBS on the left dorsolateral prefrontal cortex.
Evaluating the risk of mild serotonin syndrome in primary care: a retrospective case series of patients with treatment-resistant depression.
AME Case Rep
November 2024
Faculty of Medicine, Imperial College London, London, UK.
Background: Serotonin syndrome is an adverse drug reaction characterised by the excess of serotonin activity in the central nervous system. It is a condition of great concern in primary care where some patients, usually with treatment-resistant depression, get treatment with multiple serotonergic agents.
Case Description: This retrospective case series looked at 20 primary care patients with treatment-resistant depression who developed mild serotonin syndrome after starting a second antidepressant.
Chronobiologic treatments for mood disorders.
Handb Clin Neurol
January 2025
Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano, Italy.
Chronotherapeutics are nonpharmacologic interventions whose development stems from investigations into sleep and circadian rhythm abnormalities associated with mood disorder. These therapies utilize controlled exposure to environmental cues (light, darkness) to regulate biologic rhythms. They encompass sleep-wake manipulations (partial/total sleep deprivation, sleep phase adjustment) and light therapy approaches.
View Article and Find Full Text PDFSpecific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex.
J Affect Disord
January 2025
Department of Medicine and Surgery, Kore University of Enna, Italy; Oasi Research Institute-IRCCS, Troina, Italy. Electronic address:
Background: Clinical predictors of treatment-resistant depression could improve treatment strategies. Depressive symptom profiles at baseline are potential outcome predictors, but little evidence is available, and sex-specific profiles have been scarcely investigated.
Methods: Baseline symptom scores of 1294 patients with major depressive disorder were assessed by the Montgomery-Åsberg depression rating scale (MADRS) as part of a multicenter study by the "Group for the Studies of Resistant Depression".
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!